Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 157

1.

Molecular MRD status and outcome after transplantation in NPM1 mutated AML: results from the UK NCRI AML17 study.

Dillon R, Hills RK, Freeman SD, Potter N, Jovanovic J, Ivey A, Kanda AS, Runglall M, Foot N, Valganon M, Khwaja A, Cavenagh J, Smith ML, Ommen HB, Overgaard U, Dennis M, Knapper S, Kaur H, Taussig DC, Mehta P, Raj K, Novitzky-Basso I, Nikolousis E, Danby RD, Krishnamurthy P, Hill K, Finnegan D, Alimam S, Hurst E, Johnson P, Khan AB, Salim R, Craddock CF, Spearing RL, Gilkes AF, Gale RE, Burnett AK, Russell NH, Grimwade D.

Blood. 2020 Jan 13. pii: blood.2019002959. doi: 10.1182/blood.2019002959. [Epub ahead of print]

PMID:
31932839
2.

Allogeneic hematopoietic cell transplantation improves outcome of adults with t(6;9) acute myeloid leukemia: results from an international collaborative study.

Kayser S, Hills RK, Luskin MR, Brunner AM, Terré C, Westermann J, Menghrajani K, Shaw C, Baer MR, Elliott MA, Perl AE, Ráčil Z, Mayer J, Zak P, Szotkowski T, de Botton S, Grimwade D, Mayer K, Walter RB, Krämer A, Burnett AK, Ho AD, Platzbecker U, Thiede C, Ehninger G, Stone RM, Röllig C, Tallman MS, Estey EH, Müller-Tidow C, Russell NH, Schlenk RF, Levis MJ.

Haematologica. 2020 Jan;105(1):161-169. doi: 10.3324/haematol.2018.208678. Epub 2019 Apr 19.

3.

Correction: High expression of HMGA2 independently predicts poor clinical outcomes in acute myeloid leukemia.

Marquis M, Beaubois C, Lavallée VP, Abrahamowicz M, Danieli C, Lemieux S, Ahmad I, Wei A, Ting SB, Fleming S, Schwarer A, Grimwade D, Grey W, Hills RK, Vyas P, Russell N, Sauvageau G, Hébert J.

Blood Cancer J. 2019 Feb 28;9(3):28. doi: 10.1038/s41408-019-0190-z.

4.

Attenuated arsenic trioxide plus ATRA therapy for newly diagnosed and relapsed APL: long-term follow-up of the AML17 trial.

Russell N, Burnett A, Hills R, Betteridge S, Dennis M, Jovanovic J, Dillon R, Grimwade D; NCRI AML Working Group.

Blood. 2018 Sep 27;132(13):1452-1454. doi: 10.1182/blood-2018-05-851824. Epub 2018 Aug 10. No abstract available.

5.

High expression of HMGA2 independently predicts poor clinical outcomes in acute myeloid leukemia.

Marquis M, Beaubois C, Lavallée VP, Abrahamowicz M, Danieli C, Lemieux S, Ahmad I, Wei A, Ting SB, Fleming S, Schwarer A, Grimwade D, Grey W, Hills RK, Vyas P, Russell N, Sauvageau G, Hébert J.

Blood Cancer J. 2018 Jul 19;8(8):68. doi: 10.1038/s41408-018-0103-6. Erratum in: Blood Cancer J. 2019 Feb 28;9(3):28.

6.

Risk-adapted treatment of acute promyelocytic leukemia: results from the International Consortium for Childhood APL.

Testi AM, Pession A, Diverio D, Grimwade D, Gibson B, de Azevedo AC, Moran L, Leverger G, Elitzur S, Hasle H, van der Werff ten Bosch J, Smith O, De Rosa M, Piciocchi A, Lo Coco F, Foà R, Locatelli F, Kaspers GJL.

Blood. 2018 Jul 26;132(4):405-412. doi: 10.1182/blood-2018-03-836528. Epub 2018 May 22.

PMID:
29789356
7.

Measurable Residual Disease at Induction Redefines Partial Response in Acute Myeloid Leukemia and Stratifies Outcomes in Patients at Standard Risk Without NPM1 Mutations.

Freeman SD, Hills RK, Virgo P, Khan N, Couzens S, Dillon R, Gilkes A, Upton L, Nielsen OJ, Cavenagh JD, Jones G, Khwaja A, Cahalin P, Thomas I, Grimwade D, Burnett AK, Russell NH.

J Clin Oncol. 2018 May 20;36(15):1486-1497. doi: 10.1200/JCO.2017.76.3425. Epub 2018 Mar 30.

8.

Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party.

Schuurhuis GJ, Heuser M, Freeman S, Béné MC, Buccisano F, Cloos J, Grimwade D, Haferlach T, Hills RK, Hourigan CS, Jorgensen JL, Kern W, Lacombe F, Maurillo L, Preudhomme C, van der Reijden BA, Thiede C, Venditti A, Vyas P, Wood BL, Walter RB, Döhner K, Roboz GJ, Ossenkoppele GJ.

Blood. 2018 Mar 22;131(12):1275-1291. doi: 10.1182/blood-2017-09-801498. Epub 2018 Jan 12. Review.

9.

Clinical impact of BAALC expression in high-risk acute promyelocytic leukemia.

Lucena-Araujo AR, Pereira-Martins DA, Koury LC, Franca-Neto PL, Coelho-Silva JL, de Deus Wagatsuma VM, Melo RAM, Bittencourt R, Pagnano K, Pasquini R, Chiattone CS, Fagundes EM, Chauffaille ML, Schrier SL, Tallman MS, Ribeiro RC, Grimwade D, Ganser A, Löwenberg B, Lo-Coco F, Sanz MA, Berliner N, Rego EM.

Blood Adv. 2017 Sep 15;1(21):1807-1814. doi: 10.1182/bloodadvances.2017005926. eCollection 2017 Sep 26.

10.

Pml nuclear body disruption cooperates in APL pathogenesis and impairs DNA damage repair pathways in mice.

Voisset E, Moravcsik E, Stratford EW, Jaye A, Palgrave CJ, Hills RK, Salomoni P, Kogan SC, Solomon E, Grimwade D.

Blood. 2018 Feb 8;131(6):636-648. doi: 10.1182/blood-2017-07-794784. Epub 2017 Nov 30.

11.

The Cks1/Cks2 axis fine-tunes Mll1 expression and is crucial for MLL-rearranged leukaemia cell viability.

Grey W, Ivey A, Milne TA, Haferlach T, Grimwade D, Uhlmann F, Voisset E, Yu V.

Biochim Biophys Acta Mol Cell Res. 2018 Jan;1865(1):105-116. doi: 10.1016/j.bbamcr.2017.09.009. Epub 2017 Sep 20.

12.

Comparative genomic analysis of PML and RARA breakpoints in paired diagnosis/relapse samples of patients with acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy.

Iaccarino L, Ottone T, Hasan SK, Divona M, Cicconi L, Lavorgna S, Alfonso V, Basso G, Barragán E, Bocchia M, Rego EM, Grimwade D, Voso MT, Lo-Coco F.

Leuk Lymphoma. 2018 May;59(5):1268-1270. doi: 10.1080/10428194.2017.1369067. Epub 2017 Aug 24. No abstract available.

PMID:
28838264
13.

A PML/Slit Axis Controls Physiological Cell Migration and Cancer Invasion in the CNS.

Amodeo V, A D, Betts J, Bartesaghi S, Zhang Y, Richard-Londt A, Ellis M, Roshani R, Vouri M, Galavotti S, Oberndorfer S, Leite AP, Mackay A, Lampada A, Stratford EW, Li N, Dinsdale D, Grimwade D, Jones C, Nicotera P, Michod D, Brandner S, Salomoni P.

Cell Rep. 2017 Jul 11;20(2):411-426. doi: 10.1016/j.celrep.2017.06.047.

14.

Characteristics and outcome of patients with therapy-related acute promyelocytic leukemia front-line treated with or without arsenic trioxide.

Kayser S, Krzykalla J, Elliott MA, Norsworthy K, Gonzales P, Hills RK, Baer MR, Ráčil Z, Mayer J, Novak J, Žák P, Szotkowski T, Grimwade D, Russell NH, Walter RB, Estey EH, Westermann J, Görner M, Benner A, Krämer A, Smith BD, Burnett AK, Thiede C, Röllig C, Ho AD, Ehninger G, Schlenk RF, Tallman MS, Levis MJ, Platzbecker U.

Leukemia. 2017 Nov;31(11):2347-2354. doi: 10.1038/leu.2017.92. Epub 2017 Mar 21.

15.

Clinical relevance of failed and missing cytogenetic analysis in acute myeloid leukaemia.

Chilton L, Harrison CJ, Ashworth I, Murdy D, Burnett AK, Grimwade D, Moorman AV, Hills RK.

Leukemia. 2017 May;31(5):1234-1237. doi: 10.1038/leu.2017.37. Epub 2017 Jan 23. No abstract available.

PMID:
28111469
16.

The experience of the International Consortium on Acute Promyelocytic Leukemia in monitoring minimal residual disease in acute promyelocytic leukaemia.

Lange AP, Lima AS, Lucena-Araujo AR, Jácomo RH, Melo RA, Bittencourt RI, Pasquini R, Pagnano K, Fagundes EM, Chauffaille ML, Chiattone CS, Sanz MA, Lo-Coco F, Grimwade D, Rego EM.

Br J Haematol. 2018 Mar;180(6):915-918. doi: 10.1111/bjh.14490. Epub 2016 Dec 26. No abstract available.

PMID:
28025822
17.

Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel.

Döhner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Büchner T, Dombret H, Ebert BL, Fenaux P, Larson RA, Levine RL, Lo-Coco F, Naoe T, Niederwieser D, Ossenkoppele GJ, Sanz M, Sierra J, Tallman MS, Tien HF, Wei AH, Löwenberg B, Bloomfield CD.

Blood. 2017 Jan 26;129(4):424-447. doi: 10.1182/blood-2016-08-733196. Epub 2016 Nov 28. Review.

18.

The cryptic IRF2BP2-RARA fusion transforms hematopoietic stem/progenitor cells and induces retinoid-sensitive acute promyelocytic leukemia.

Jovanovic JV, Chillón MC, Vincent-Fabert C, Dillon R, Voisset E, Gutiérrez NC, Sanz RG, Lopez AA, Morgan YG, Lok J, Solomon E, Duprez E, Díaz MG, Grimwade D.

Leukemia. 2017 Mar;31(3):747-751. doi: 10.1038/leu.2016.338. Epub 2016 Nov 22. No abstract available.

PMID:
27872498
19.

Expression of CD33 is a predictive factor for effect of gemtuzumab ozogamicin at different doses in adult acute myeloid leukaemia.

Khan N, Hills RK, Virgo P, Couzens S, Clark N, Gilkes A, Richardson P, Knapper S, Grimwade D, Russell NH, Burnett AK, Freeman SD.

Leukemia. 2017 May;31(5):1059-1068. doi: 10.1038/leu.2016.309. Epub 2016 Oct 31.

20.

Normal Hematopoietic Progenitor Subsets Have Distinct Reactive Oxygen Species, BCL2 and Cell-Cycle Profiles That Are Decoupled from Maturation in Acute Myeloid Leukemia.

Khan N, Hills RK, Knapper S, Steadman L, Qureshi U, Rector JL, Bradbury C, Russell NH, Vyas P, Burnett AK, Grimwade D, Hole PS, Freeman SD.

PLoS One. 2016 Sep 26;11(9):e0163291. doi: 10.1371/journal.pone.0163291. eCollection 2016.

21.

Assessment of Minimal Residual Disease in Standard-Risk AML.

Hills RK, Ivey A, Grimwade D; UK National Cancer Research Institute (NCRI) AML Working Group.

N Engl J Med. 2016 Aug 11;375(6):e9. doi: 10.1056/NEJMc1603847. No abstract available.

PMID:
27509124
22.

Just 1 test to diagnose AML?!!

Dillon R, Grimwade D.

Blood. 2016 Jul 7;128(1):8-10. doi: 10.1182/blood-2016-05-715060. No abstract available.

PMID:
27389539
23.

Genetically distinct leukemic stem cells in human CD34- acute myeloid leukemia are arrested at a hemopoietic precursor-like stage.

Quek L, Otto GW, Garnett C, Lhermitte L, Karamitros D, Stoilova B, Lau IJ, Doondeea J, Usukhbayar B, Kennedy A, Metzner M, Goardon N, Ivey A, Allen C, Gale R, Davies B, Sternberg A, Killick S, Hunter H, Cahalin P, Price A, Carr A, Griffiths M, Virgo P, Mackinnon S, Grimwade D, Freeman S, Russell N, Craddock C, Mead A, Peniket A, Porcher C, Vyas P.

J Exp Med. 2016 Jul 25;213(8):1513-35. doi: 10.1084/jem.20151775. Epub 2016 Jul 4.

24.

Distinct evolution and dynamics of epigenetic and genetic heterogeneity in acute myeloid leukemia.

Li S, Garrett-Bakelman FE, Chung SS, Sanders MA, Hricik T, Rapaport F, Patel J, Dillon R, Vijay P, Brown AL, Perl AE, Cannon J, Bullinger L, Luger S, Becker M, Lewis ID, To LB, Delwel R, Löwenberg B, Döhner H, Döhner K, Guzman ML, Hassane DC, Roboz GJ, Grimwade D, Valk PJ, D'Andrea RJ, Carroll M, Park CY, Neuberg D, Levine R, Melnick AM, Mason CE.

Nat Med. 2016 Jul;22(7):792-9. doi: 10.1038/nm.4125. Epub 2016 Jun 20.

25.

Assessment of Minimal Residual Disease in Standard-Risk AML.

Ivey A, Hills RK, Simpson MA, Jovanovic JV, Gilkes A, Grech A, Patel Y, Bhudia N, Farah H, Mason J, Wall K, Akiki S, Griffiths M, Solomon E, McCaughan F, Linch DC, Gale RE, Vyas P, Freeman SD, Russell N, Burnett AK, Grimwade D; UK National Cancer Research Institute AML Working Group.

N Engl J Med. 2016 Feb 4;374(5):422-33. doi: 10.1056/NEJMoa1507471. Epub 2016 Jan 20.

26.

Molecular landscape of acute myeloid leukemia in younger adults and its clinical relevance.

Grimwade D, Ivey A, Huntly BJ.

Blood. 2016 Jan 7;127(1):29-41. doi: 10.1182/blood-2015-07-604496. Epub 2015 Dec 10. Review.

27.

High ΔNp73/TAp73 ratio is associated with poor prognosis in acute promyelocytic leukemia.

Lucena-Araujo AR, Kim HT, Thomé C, Jacomo RH, Melo RA, Bittencourt R, Pasquini R, Pagnano K, Glória AB, Chauffaille Mde L, Athayde M, Chiattone CS, Mito I, Bendlin R, Souza C, Bortolheiro C, Coelho-Silva JL, Schrier SL, Tallman MS, Grimwade D, Ganser A, Berliner N, Ribeiro RC, Lo-Coco F, Löwenberg B, Sanz MA, Rego EM.

Blood. 2015 Nov 12;126(20):2302-6. doi: 10.1182/blood-2015-01-623330. Epub 2015 Oct 1.

28.

Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial.

Burnett AK, Russell NH, Hills RK, Bowen D, Kell J, Knapper S, Morgan YG, Lok J, Grech A, Jones G, Khwaja A, Friis L, McMullin MF, Hunter A, Clark RE, Grimwade D; UK National Cancer Research Institute Acute Myeloid Leukaemia Working Group.

Lancet Oncol. 2015 Oct;16(13):1295-305. doi: 10.1016/S1470-2045(15)00193-X. Epub 2015 Sep 14.

PMID:
26384238
29.

Leukemia diagnosis: today and tomorrow.

Béné MC, Grimwade D, Haferlach C, Haferlach T, Zini G; European LeukemiaNet.

Eur J Haematol. 2015 Oct;95(4):365-73. doi: 10.1111/ejh.12603. Epub 2015 Jul 26. Review.

PMID:
26110830
30.

An immunophenotypic pre-treatment predictor for poor response to induction chemotherapy in older acute myeloid leukaemia patients: blood frequency of CD34+ CD38 low blasts.

Khan N, Freeman SD, Virgo P, Couzens S, Richardson P, Thomas I, Grech A, Vyas P, Grimwade D, Russell NH, Burnett AK, Hills RK.

Br J Haematol. 2015 Jul;170(1):80-4. doi: 10.1111/bjh.13398. Epub 2015 Apr 14.

PMID:
25876768
31.

Downregulation of the Wnt inhibitor CXXC5 predicts a better prognosis in acute myeloid leukemia.

Kühnl A, Valk PJ, Sanders MA, Ivey A, Hills RK, Mills KI, Gale RE, Kaiser MF, Dillon R, Joannides M, Gilkes A, Haferlach T, Schnittger S, Duprez E, Linch DC, Delwel R, Löwenberg B, Baldus CD, Solomon E, Burnett AK, Grimwade D.

Blood. 2015 May 7;125(19):2985-94. doi: 10.1182/blood-2014-12-613703. Epub 2015 Mar 24.

32.

Defining minimal residual disease in acute myeloid leukemia: which platforms are ready for "prime time"?

Grimwade D, Freeman SD.

Hematology Am Soc Hematol Educ Program. 2014 Dec 5;2014(1):222-33. doi: 10.1182/asheducation-2014.1.222. Epub 2014 Nov 18. Review.

PMID:
25696859
33.

Minimal residual disease-directed therapy in acute myeloid leukemia.

Kayser S, Schlenk RF, Grimwade D, Yosuico VE, Walter RB.

Blood. 2015 Apr 9;125(15):2331-5. doi: 10.1182/blood-2014-11-578815. Epub 2015 Jan 28. Review. No abstract available.

PMID:
25631772
34.

Arsenic trioxide-based therapy of relapsed acute promyelocytic leukemia: registry results from the European LeukemiaNet.

Lengfelder E, Lo-Coco F, Ades L, Montesinos P, Grimwade D, Kishore B, Ramadan SM, Pagoni M, Breccia M, Huerta AJ, Nloga AM, González-Sanmiguel JD, Schmidt A, Lambert JF, Lehmann S, Di Bona E, Cassinat B, Hofmann WK, Görlich D, Sauerland MC, Fenaux P, Sanz M; European LeukemiaNet.

Leukemia. 2015 May;29(5):1084-91. doi: 10.1038/leu.2015.12. Epub 2015 Jan 28.

PMID:
25627637
35.

PcG methylation of the HIST1 cluster defines an epigenetic marker of acute myeloid leukemia.

Tiberi G, Pekowska A, Oudin C, Ivey A, Autret A, Prebet T, Koubi M, Lembo F, Mozziconacci MJ, Bidaut G, Chabannon C, Grimwade D, Vey N, Spicuglia S, Calmels B, Duprez E.

Leukemia. 2015 May;29(5):1202-6. doi: 10.1038/leu.2014.339. Epub 2014 Dec 8. No abstract available.

PMID:
25482132
36.

Prognostic value of monitoring a candidate immunophenotypic leukaemic stem/progenitor cell population in patients allografted for acute myeloid leukaemia.

Bradbury C, Houlton AE, Akiki S, Gregg R, Rindl M, Khan J, Ward J, Khan N, Griffiths M, Nagra S, Hills R, Burnett A, Russell N, Vyas P, Grimwade D, Craddock C, Freeman SD.

Leukemia. 2015 Apr;29(4):988-91. doi: 10.1038/leu.2014.327. Epub 2014 Nov 26. No abstract available.

37.

Defining minimal residual disease in acute myeloid leukemia: which platforms are ready for "prime time"?

Grimwade D, Freeman SD.

Blood. 2014 Nov 27;124(23):3345-55. doi: 10.1182/blood-2014-05-577593. Epub 2014 Jul 21. Review.

PMID:
25049280
38.

Internal tandem duplication of the FLT3 gene confers poor overall survival in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based chemotherapy: an International Consortium on Acute Promyelocytic Leukemia study.

Lucena-Araujo AR, Kim HT, Jacomo RH, Melo RA, Bittencourt R, Pasquini R, Pagnano K, Fagundes EM, Chauffaille Mde L, Chiattone CS, Lima AS, Ruiz-Argüelles G, Undurraga MS, Martinez L, Kwaan HC, Gallagher R, Niemeyer CM, Schrier SL, Tallman MS, Grimwade D, Ganser A, Berliner N, Ribeiro RC, Lo-Coco F, Löwenberg B, Sanz MA, Rego EM.

Ann Hematol. 2014 Dec;93(12):2001-10. doi: 10.1007/s00277-014-2142-9. Epub 2014 Jul 2.

PMID:
24981688
39.

Can we say farewell to monitoring minimal residual disease in acute promyelocytic leukaemia?

Grimwade D, Jovanovic JV, Hills RK.

Best Pract Res Clin Haematol. 2014 Mar;27(1):53-61. doi: 10.1016/j.beha.2014.04.002. Epub 2014 Apr 12. Review.

PMID:
24907017
40.

Prognostic impact of KMT2E transcript levels on outcome of patients with acute promyelocytic leukaemia treated with all-trans retinoic acid and anthracycline-based chemotherapy: an International Consortium on Acute Promyelocytic Leukaemia study.

Lucena-Araujo AR, Kim HT, Jacomo RH, Melo RA, Bittencourt R, Pasquini R, Pagnano K, Fagundes EM, de Lourdes Chauffaille M, Chiattone CS, Lima AS, Kwaan HC, Gallagher R, Niemeyer CM, Schrier SL, Tallman MS, Grimwade D, Ganser A, Berliner N, Ribeiro RC, Lo-Coco F, Löwenberg B, Sanz MA, Rego EM.

Br J Haematol. 2014 Aug;166(4):540-9. doi: 10.1111/bjh.12921. Epub 2014 May 3.

PMID:
24796963
41.

Topoisomerase II and leukemia.

Pendleton M, Lindsey RH Jr, Felix CA, Grimwade D, Osheroff N.

Ann N Y Acad Sci. 2014 Mar;1310:98-110. doi: 10.1111/nyas.12358. Epub 2014 Feb 3. Review.

42.

Loss of imprinting at the 14q32 domain is associated with microRNA overexpression in acute promyelocytic leukemia.

Manodoro F, Marzec J, Chaplin T, Miraki-Moud F, Moravcsik E, Jovanovic JV, Wang J, Iqbal S, Taussig D, Grimwade D, Gribben JG, Young BD, Debernardi S.

Blood. 2014 Mar 27;123(13):2066-74. doi: 10.1182/blood-2012-12-469833. Epub 2014 Feb 3.

PMID:
24493669
43.

Wilms' Tumour 1 (WT1) peptide vaccination in patients with acute myeloid leukaemia induces short-lived WT1-specific immune responses.

Uttenthal B, Martinez-Davila I, Ivey A, Craddock C, Chen F, Virchis A, Kottaridis P, Grimwade D, Khwaja A, Stauss H, Morris EC.

Br J Haematol. 2014 Feb;164(3):366-75. doi: 10.1111/bjh.12637. Epub 2013 Nov 16.

44.

Prognostic significance of additional cytogenetic abnormalities and FLT3 mutations in acute promyelocytic leukemia.

Dillon R, Grimwade D.

Leuk Lymphoma. 2014 Jul;55(7):1444-6. doi: 10.3109/10428194.2013.868458. Epub 2014 Jan 28. No abstract available.

PMID:
24313832
45.

Prognostic relevance of treatment response measured by flow cytometric residual disease detection in older patients with acute myeloid leukemia.

Freeman SD, Virgo P, Couzens S, Grimwade D, Russell N, Hills RK, Burnett AK.

J Clin Oncol. 2013 Nov 10;31(32):4123-31. doi: 10.1200/JCO.2013.49.1753. Epub 2013 Sep 23.

PMID:
24062403
46.

NUP98-NSD1 fusion in association with FLT3-ITD mutation identifies a prognostically relevant subgroup of pediatric acute myeloid leukemia patients suitable for monitoring by real time quantitative PCR.

Akiki S, Dyer SA, Grimwade D, Ivey A, Abou-Zeid N, Borrow J, Jeffries S, Caddick J, Newell H, Begum S, Tawana K, Mason J, Velangi M, Griffiths M.

Genes Chromosomes Cancer. 2013 Nov;52(11):1053-64. doi: 10.1002/gcc.22100. Epub 2013 Sep 2.

PMID:
23999921
47.

Acute myeloid leukaemia with mutated NPM1 presenting with extensive bone marrow necrosis and Charcot-Leyden crystals.

Taylor G, Ivey A, Milner B, Grimwade D, Culligan D.

Int J Hematol. 2013 Sep;98(3):267-8. doi: 10.1007/s12185-013-1394-9. Epub 2013 Jul 25.

PMID:
23884732
48.

Establishing optimal quantitative-polymerase chain reaction assays for routine diagnosis and tracking of minimal residual disease in JAK2-V617F-associated myeloproliferative neoplasms: a joint European LeukemiaNet/MPN&MPNr-EuroNet (COST action BM0902) study.

Jovanovic JV, Ivey A, Vannucchi AM, Lippert E, Oppliger Leibundgut E, Cassinat B, Pallisgaard N, Maroc N, Hermouet S, Nickless G, Guglielmelli P, van der Reijden BA, Jansen JH, Alpermann T, Schnittger S, Bench A, Tobal K, Wilkins B, Cuthill K, McLornan D, Yeoman K, Akiki S, Bryon J, Jeffries S, Jones A, Percy MJ, Schwemmers S, Gruender A, Kelley TW, Reading S, Pancrazzi A, McMullin MF, Pahl HL, Cross NC, Harrison CN, Prchal JT, Chomienne C, Kiladjian JJ, Barbui T, Grimwade D.

Leukemia. 2013 Oct;27(10):2032-9. doi: 10.1038/leu.2013.219. Epub 2013 Jul 17.

49.

Hyperdiploidy with 49-65 chromosomes represents a heterogeneous cytogenetic subgroup of acute myeloid leukemia with differential outcome.

Chilton L, Hills RK, Harrison CJ, Burnett AK, Grimwade D, Moorman AV.

Leukemia. 2014 Feb;28(2):321-8. doi: 10.1038/leu.2013.198. Epub 2013 Jul 1.

PMID:
23812419
50.

The epigenetic regulator PLZF represses L1 retrotransposition in germ and progenitor cells.

Puszyk W, Down T, Grimwade D, Chomienne C, Oakey RJ, Solomon E, Guidez F.

EMBO J. 2013 Jul 3;32(13):1941-52. doi: 10.1038/emboj.2013.118. Epub 2013 May 31.

Supplemental Content

Loading ...
Support Center